Enhabit Earnings Call Transcripts
Fiscal Year 2025
-
Final home health rate cuts were less severe than expected, supporting profitability and investment plans for 2026. Strategic focus includes disciplined M&A, payer innovation, and operational efficiency, with mid- to high-single digit growth targeted for both home health and hospice.
-
Hospice outperformed expectations, while home health growth and margin depend on the final CMS rule. Operational pilots and payer strategies are offsetting regulatory risks, and deleveraging has improved financial flexibility. Litigation remains ongoing.
-
Q3 saw strong revenue and EBITDA growth, led by record hospice performance and improved home health metrics. Guidance for full-year revenue, EBITDA, and free cash flow was raised, while leverage and costs improved. Strategic initiatives are in place to address upcoming CMS rate changes.
-
Growth in home health and hospice is driven by payer strategy, operational pilots, and improved contracting. Facing a significant Medicare rate cut, the company is piloting efficiency initiatives and advocating for regulatory relief. Debt reduction, technology investment, and a strong hospice platform position the business for future growth.
-
Q2 2025 saw year-over-year and sequential revenue and adjusted EBITDA growth, with hospice delivering strong double-digit gains and home health stabilizing Medicare census. Updated guidance reflects continued momentum, while regulatory headwinds and a CEO transition are on the horizon.
-
Achieved full-service provider status in 2024, driving balanced payer mix and growth in both home health and hospice. Industry trends show rising Medicare Advantage utilization and declining traditional Medicare, with operational and cost initiatives supporting margin stability.
-
Q1 2025 delivered strong sequential growth, margin expansion, and deleveraging, with home health and hospice segments both showing robust volume and profitability gains. Cost efficiencies, improved payer mix, and strong cash flow supported a reaffirmed 2025 outlook.
Fiscal Year 2024
-
Sequential revenue and adjusted EBITDA growth in Q4 2024 was driven by strong hospice and payer innovation contract momentum, with 2025 guidance projecting continued improvement and margin expansion. Strategic cost actions and De Novo expansion support growth, while CMS payment and wage inflation remain key risks.
-
A new multi-year UnitedHealthcare agreement positions the provider for growth, with favorable contract terms and a focus on shifting more business to payer innovation models. Home health and hospice expect mid to high single-digit growth, supported by cost savings, technology adoption, and stabilized labor. Regulatory and market dynamics remain key watch areas.
-
Q3 saw sequential volume growth, strong hospice performance, and a 5.6% rise in Home Health admissions, offset by lower recertifications and hurricane impacts. Adjusted EBITDA rose 5.6% year-over-year, with 2024 guidance revised due to weather and operational headwinds.
-
Payer innovation strategy enabled a shift from UnitedHealthcare to a diversified contract base, improving reimbursement rates and reducing risk. Hospice segment growth is driven by operational improvements and business development. For 2025, moderate Medicare headwinds are expected, but non-Medicare and hospice segments show strong growth potential.
-
Q2 2024 saw strong execution of strategic initiatives, with adjusted EBITDA up 5.4% year-over-year despite a slight revenue decline. Home health admissions grew 6.4%, and hospice census increased, while cost controls and payer mix improvements supported margins.
-
Management outlined a strategy focused on stabilizing Medicare mix, expanding payer contracts, and growing through de novo locations. Operational efficiency and labor initiatives are driving improved retention and productivity, while financial guidance points to mid- to high-single-digit growth and a focus on deleveraging.